KONFIDENT phase 3 trial results demonstrated significantly faster symptom relief with sebetralstat compared to placebo.

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Immunosuppressive therapy may help reduce gastrointestinal (GI) symptoms among patients with systemic sclerosis (SSc), according to study results published in RMD Open.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.